Beyond Testing: Rethinking Access in Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
JCO Global Oncology · 2026-07 · 12 (7)
DOI: 10.1200/go-26-00307 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Global Oncology, 2026-07. Verfasst von Ana Carolina de Jesus Paniza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina do ABC-FMABC, Santo André, SP, Brasil. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Faculdade de Medicina do ABC-FMABC, Santo André, SP, Brasil.
- Department of Oncology, Queen's University, Kingston, ON, Canada.
- Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL.
ORCID-Profile: Ana Carolina de Jesus Paniza, Fabio Ynoe Moraes, Gilberto Lopes
Zitieren
APA
Paniza, A. C. J., Moraes, F. Y., & Lopes, G. (2026). Beyond Testing: Rethinking Access in Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer. JCO Global Oncology, 12(7). https://doi.org/10.1200/go-26-00307
Vancouver
Paniza ACJ, Moraes FY, Lopes G. Beyond Testing: Rethinking Access in Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer. JCO Global Oncology. 2026;12(7). doi:10.1200/go-26-00307
BibTeX
@article{Paniza2026,
author = {Paniza, Ana Carolina de Jesus and Moraes, Fabio Ynoe and Lopes, Gilberto},
title = {Beyond Testing: Rethinking Access in Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {7},
doi = {10.1200/go-26-00307}
}
EUVIMED